远志与石菖蒲治疗阿尔茨海默病的系统评价与Meta分析
该系统评价与Meta分析纳入16项随机对照试验共1103例AD患者,评估远志与石菖蒲配伍的疗效与安全性;结果显示联合常规药物在MMSE、ADL、ADAS-cog及临床有效率上优于单用常规药物,且不良事件未增加;但证据质量很低至低。
要点
- 远志与石菖蒲联合常规药物可改善AD患者认知与日常活动能力。
- 联合治疗组不良事件风险未显著高于单用常规药物组。
- 证据质量很低至低,结论需谨慎解读。
核心结论
- 与单用常规药物相比,远志与石菖蒲联合常规药物可能作为改善AD整体认知与功能的替代疗法。
- 远志与石菖蒲作为辅助治疗在疗效上对AD产生更好治疗反应且不增加不良事件风险。
- 现有证据质量很低至低,限制了对研究发现的信心。
研究设计与样本
- 系统检索8个数据库截至2023年6月26日的随机对照试验。
- 纳入16项合格研究,共1103例AD参与者。
- 采用Cochrane偏倚风险评估工具评价纳入研究质量。
- 效应量采用均数差(MD)及95%置信区间(CI)和风险比(RR)。
- 使用RevMan 5.4和Stata 16进行数据分析与评价。
主要发现
- 远志与石菖蒲联合常规药物对比单用常规药物:MMSE [MD=2.57, 95%CI: (1.44, 3.69); p<0.00001; I²=86%]。
- 远志与石菖蒲联合常规药物对比单用常规药物:ADL [MD=-3.19, 95%CI: (-4.29, -2.09); p<0.00001; I²=0%]。
- 远志与石菖蒲联合常规药物对比单用常规药物:ADAS-cog [MD=-2.09, 95%CI: (-3.07, -1.10); p<0.0001; I²=0%]。
- 远志与石菖蒲联合常规药物对比单用常规药物:临床有效率 [RR=1.27, 95%CI: (1.12, 1.44); p=0.0002; I²=0%]。
- 远志与石菖蒲联合常规药物对比单用常规药物:不良事件 [RR=0.65, 95%CI: (0.35, 1.19); p=0.16; I²=0%]。
关键数值与推荐
- 主要结局评估指标包括简易精神状态检查(MMSE)、日常生活活动能力(ADL)和AD评估量表-认知分量表(ADAS-cog)。
- 次要结局包括临床有效率和不良事件。
- 联合治疗组MMSE的MD=2.57(95%CI: 1.44至3.69),p<0.00001,I²=86%。
- 联合治疗组ADL的MD=-3.19(95%CI: -4.29至-2.09),p<0.00001,I²=0%。
- 联合治疗组ADAS-cog的MD=-2.09(95%CI: -3.07至-1.10),p<0.0001,I²=0%。
临床怎么用
- 在常规药物治疗基础上,可考虑联合远志与石菖蒲以改善AD患者整体认知与日常功能。
- 联合用药未显示增加不良事件风险,但需结合证据质量低谨慎决策。
- 单用远志与石菖蒲替代常规药物证据不足,不建议单独用于替代常规治疗。
局限性
- 纳入研究的可用证据质量很低至低,限制了对研究结果的信心。
- MMSE分析异质性较高(I²=86%)。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The complexity of Chinese medicine treatment for Alzheimer's disease (AD) utilizing a multi-herb therapy makes the evidence in current studies insufficient. Herb pairs are the most fundamental form of multi-herb formulae. Among the Chinese herbal formulas for AD treatment, Polygala tenuifolia (PT) and Acorus tatarinowii (AT) appeared as the most commonly used herbal pairs in combination. Objective: The aim of this study is to evaluate the clinical efficacy and safety of the combination of PT and AT in the treatment of AD. Methods: We systematically searched and screened randomized controlled trials of pairing PT and AT for the treatment of AD patients in eight databases with a search deadline of June 26, 2023. Authors, year of publication, title, and basic information such as subject characteristics (age, sex, and race), course of disease, control interventions, dose, and treatment duration were extracted from the screened studies. Primary outcomes assessed included mini-mental state examination (MMSE), activities of daily living (ADL), and AD assessment scale-cognitive subscale (ADAS-cog), while secondary outcomes included efficiency and adverse events. The quality of the included studies was assessed using the Cochrane risk of bias tool. The mean difference with 95% confidence intervals (MD [95% CI]) and risk ratio (RR) was selected as the effect size, and the data were analyzed and evaluated using RevMan 5.4 and Stata 16. Results: A total of sixteen eligible and relevant studies involving 1103 AD participants were included. The combination of PT and AT plus conventional drugs was superior to single conventional drugs in MMSE [MD = 2.57, 95%CI: (1.44, 3.69); p < 0.00001; I 2 = 86%], ADL [MD = -3.19, 95%CI: (-4.29, -2.09); p < 0.00001; I 2 = 0%], and ADAS-cog scores [MD = -2.09, 95%CI: (-3.07, -1.10); p < 0.0001; I 2 = 0%]. The combination of PT and AT plus conventional drugs had a significantly more favorable benefit in clinical effectiveness [RR = 1.27, 95%CI: (1.12, 1.44); p = 0.0002; I 2 = 0%]. Adverse events were not increased with the combination of PT and AT plus conventional drugs compared to conventional drugs [RR = 0.65, 95%CI: (0.35, 1.19); p = 0.16; I 2 = 0%]. The experimental group treated with the combination of PT and AT alone for AD was comparable in MMSE, ADL, and ADAS-cog scores compared with the control group treated with single conventional drugs. Conclusion: Compared to single conventional drugs, the combination of PT and AT may be used as an alternative therapy to improve global cognition and functioning in AD, and the combination of PT and AT as adjunctive therapy appears to produce a better therapeutic response to AD in terms of efficacy without increasing the risk of adverse events. However, the very low to low quality of available evidence limits confidence in the findings. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023444156.
引用
- Zhang Y, Tian J, Ni J, et al. Polygala tenuifolia and Acorus tatarinowii in the treatment of Alzheimer's disease: a systematic review and meta-analysis. Front Pharmacol. 2024. PMID: 38283842. doi:10.3389/fphar.2023.1268000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。